9.52 USD
▼-0.25-2.56%
盘后 9.50 -0.21%
2026-11-19
市值
$1.40B
市盈率
—
EPS
-3.35
股息率
—
52 周区间
7.95 – 18.48
成交量
9.97M
Beta
1.82
目标价
22.78
52W 低 7.9552W 高 18.48
价格走势
公司简介
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;...